BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval
Breyanzi’s EU Approval Will Introduce A Third CAR-T Therapy To The LBCL Market
Each dose of Breyanzi is created by collecting and genetically modifying a patient’s own immune cells to treat their cancer • Source: Alamy (Alamy Stock Photo)
